Single-domain antibodies recognize selectively small oligomeric forms of amyloid β, prevent Aβ-induced neurotoxicity and inhibit fibril formation

Arbabi Ghahroudi, 1997, Selection and identification of single domain antibody fragments from camel heavy-chain antibodies, FEBS Lett., 414, 521, 10.1016/S0014-5793(97)01062-4 Bard, 2000, Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease, Nat. Med., 6, 916, 10.1038/78682 Barelli, 1997, Mol. Med., 3, 695, 10.1007/BF03401708 Bitan, 2003, Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways, Proc. Natl. Acad. Sci. U.S.A., 100, 330, 10.1073/pnas.222681699 Braak, 1991, Neuropathological stageing of Alzheimer-related changes, Acta Neuropathol. (Berl.), 82, 239, 10.1007/BF00308809 Cardoso, 2000, Neutralizing human anti crotoxin scFv isolated from a nonimmunized phage library, Scand. J. Immunol., 51, 337, 10.1046/j.1365-3083.2000.00709.x Cleary, 2005, Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function, Nat. Neurosci., 8, 79, 10.1038/nn1372 De Genst, 2006, Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies, Proc. Natl. Acad. Sci. U.S.A., 103, 4586, 10.1073/pnas.0505379103 Delacourte, 2002, Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease, Neurology, 59, 398, 10.1212/WNL.59.3.398 Desmyter, 2002, Three Camelid VHH domains in complex with porcine pancreatic alpha-amylase—inhibition and versatility of binding topology, J. Biol. Chem., 277, 23645, 10.1074/jbc.M202327200 Desmyter, 1996, Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme, Nat. Struct. Biol., 3, 803, 10.1038/nsb0996-803 Dodel, 2003, Immunotherapy for Alzheimer’s disease, Lancet Neurol., 2, 215, 10.1016/S1474-4422(03)00349-1 Friguet, 1985, Measurements of the true affinity constant in solution of antigen–antibody complexes by enzyme-linked immunosorbent assay, J. Immunol. Methods, 77, 305, 10.1016/0022-1759(85)90044-4 Glenner, 1980, Amyloid deposits and amyloidosis. The β-fibrilloses, N. Engl. J. Med., 302, 1283, 10.1056/NEJM198006053022305 Gouras, 2000, Intraneuronal Abeta 42 accumulation in human brain, Am. J. Pathol., 156, 15, 10.1016/S0002-9440(10)64700-1 Haass, 2007, Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid β-peptide, Nat. Rev. Mol. Cell Biol., 8, 101112, 10.1038/nrm2101 Habicht, 2007, Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils, Proc. Natl. Acad. Sci. U.S.A., 104, 19232, 10.1073/pnas.0703793104 Hamers-Casterman, 1993, Naturally occurring antibodies devoid of light chains, Nature, 363, 446, 10.1038/363446a0 Hartley, 1999, Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons, J. Neurosci., 19, 8876, 10.1523/JNEUROSCI.19-20-08876.1999 Johnson-Wood, 1997, Amyloid precursor protein processing and Abeta 42 deposition in a transgenic mouse model of Alzheimer disease, Proc. Natl. Acad. Sci. U.S.A., 94, 1550, 10.1073/pnas.94.4.1550 Kayed, 2003, Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis, Science, 300, 486, 10.1126/science.1079469 Kuo, 1996, Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains, J. Biol. Chem., 271, 4077, 10.1074/jbc.271.8.4077 Lacor, 2004, Synaptic targeting by Alzheimer’s-related amyloid beta oligomers, J. Neurosci., 24, 10191, 10.1523/JNEUROSCI.3432-04.2004 Lafaye, 1995, Similar binding activity for a neutralizing anti-tetanus toxoid human monoclonal antibody and its bacterially expressed Fab, Res. Immunol., 146, 373, 10.1016/0923-2494(96)81041-8 Lambert, 2007, Monoclonal antibodies that target pathological assemblies of Abeta, J. Neurochem., 100, 23, 10.1111/j.1471-4159.2006.04157.x Lapresle, 1988, Enzyme immunoassay using monoclonal antibodies to study conformational changes of human serum albumin, Anal. Biochem., 174, 308, 10.1016/0003-2697(88)90550-7 Lee, 2006, Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice, J. Biol. Chem., 281, 4292, 10.1074/jbc.M511018200 Legleiter, 2004, Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy, J. Mol. Biol., 335, 997, 10.1016/j.jmb.2003.11.019 LeVine, 1993, Thioflavine T interaction with synthetic Alzheimer’s disease beta-amyloid peptides: detection of amyloid aggregation in solution, Protein Sci., 2, 404, 10.1002/pro.5560020312 Liu, 2004, Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent Abeta-induced neurotoxicity, Biochemistry, 43, 6959, 10.1021/bi049933o Mochizuki, 2000, Aβ42-positive non-pyramidal neurons around amyloid plaques in Alzheimer’s disease, Lancet, 355, 42, 10.1016/S0140-6736(99)04937-5 Mosmann, 1983, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J. Immunol. Methods, 65, 55, 10.1016/0022-1759(83)90303-4 Muyldermans, 1994, Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains, Protein Eng., 7, 1129, 10.1093/protein/7.9.1129 Muyldermans, 2001, Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains, Trends Biochem. Sci., 26, 230, 10.1016/S0968-0004(01)01790-X Solomon, 2002, Anti-aggregating antibodies, a new approach towards treatment of conformational diseases, Curr. Med. Chem., 9, 1737, 10.2174/0929867023369141 Takahashi, 2002, Intraneuronal alzheimer Aβ42 accumulates in multivesicular bodies and is associated with synaptic pathology, Am. J. Pathol., 161, 1869, 10.1016/S0002-9440(10)64463-X Townsend, 2006, Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers, J. Physiol., 572, 477, 10.1113/jphysiol.2005.103754 Walsh, 2004, Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration, Protein Pept. Lett., 11, 213, 10.2174/0929866043407174 Wegiel, 2007, Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration, Acta Neuropathol. (Berl.), 10.1007/s00401-006-0191-4 Westermark, 2005, Aspects on human amyloid forms and their fibril polypeptides, FEBS Lett., 272, 5942, 10.1111/j.1742-4658.2005.05024.x Wirths, 2002, Intraneuronal APP/A beta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice, Brain Pathol., 12, 275, 10.1111/j.1750-3639.2002.tb00442.x Yamaguchi, 1998, Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques, Acta Neuropathol., 95, 217, 10.1007/s004010050790 Yan, 2006, Abeta42 is more rigid than Abeta40 at the C terminus: implications for Abeta aggregation and toxicity, J. Mol. Biol., 364, 853, 10.1016/j.jmb.2006.09.046 Zameer, 2006, Single Chain Fv antibodies against the 25–35 Abeta fragment inhibit aggregation and toxicity of Abeta 42, Biochemistry, 45, 11532, 10.1021/bi060601o